A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation

Christopher A. Ludlam, Mark P. Smith, Massimo Morfini, Alessandro Gringeri, Elena Santagostino, Geoffrey F. Savidge

Research output: Contribution to journalArticle

Abstract

After surgery in haemophilia, haemostasis is difficult to maintain in the presence of an antifactor VIII antibody. This study assessed the pharmacokinetics of recombinant activated factor VII (rFVIIa) and its efficacy in securing post-operative haemostasis in haemophiliacs with inhibitors. Continuous infusion of rFVIIa was evaluated for elective major orthopaedic surgery in nine patients with neutralizing antibodies to FVIII and at high risk of bleeding. After an initial preoperative bolus of 90 μg/kg, rFVIIa was infused at a fixed rate of 50 μg/kg/h for a median of 20 d (range 7-20 d). The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively. The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively. Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55) ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively. Post-operatively, there were bleeds in six patients, which settled readily after a single bolus of rFVIIa (60 μg/kg). There was a good clinical outcome for all patients. These data indicate that rFVIIa infusion at 50 μg/kg/h achieves continuous plasma FVII procoagulant activity in excess of 30 IU/ml (12-15 nmol/l) and provides adequate haemostatic control for inhibitor patients during major orthopaedic surgery.

Original languageEnglish
Pages (from-to)808-813
Number of pages6
JournalBritish Journal of Haematology
Volume120
Issue number5
DOIs
Publication statusPublished - Mar 1 2003

Fingerprint

Factor VIIa
Orthopedics
Pharmacokinetics
Prospective Studies
Hemostasis
Coagulants
Hemophilia A
Hemostatics
recombinant FVIIa
Neutralizing Antibodies
Hemorrhage
Antibodies

Keywords

  • Antifactor VIII antibody
  • Haemophilia
  • Orthopaedic surgery
  • Pharmacokinetic study
  • Recombinant VIIa

ASJC Scopus subject areas

  • Hematology

Cite this

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery : A pharmacokinetic and efficacy evaluation. / Ludlam, Christopher A.; Smith, Mark P.; Morfini, Massimo; Gringeri, Alessandro; Santagostino, Elena; Savidge, Geoffrey F.

In: British Journal of Haematology, Vol. 120, No. 5, 01.03.2003, p. 808-813.

Research output: Contribution to journalArticle

@article{b4b5fc7cfbda488284d481c3ab0705c7,
title = "A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation",
abstract = "After surgery in haemophilia, haemostasis is difficult to maintain in the presence of an antifactor VIII antibody. This study assessed the pharmacokinetics of recombinant activated factor VII (rFVIIa) and its efficacy in securing post-operative haemostasis in haemophiliacs with inhibitors. Continuous infusion of rFVIIa was evaluated for elective major orthopaedic surgery in nine patients with neutralizing antibodies to FVIII and at high risk of bleeding. After an initial preoperative bolus of 90 μg/kg, rFVIIa was infused at a fixed rate of 50 μg/kg/h for a median of 20 d (range 7-20 d). The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively. The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively. Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55) ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively. Post-operatively, there were bleeds in six patients, which settled readily after a single bolus of rFVIIa (60 μg/kg). There was a good clinical outcome for all patients. These data indicate that rFVIIa infusion at 50 μg/kg/h achieves continuous plasma FVII procoagulant activity in excess of 30 IU/ml (12-15 nmol/l) and provides adequate haemostatic control for inhibitor patients during major orthopaedic surgery.",
keywords = "Antifactor VIII antibody, Haemophilia, Orthopaedic surgery, Pharmacokinetic study, Recombinant VIIa",
author = "Ludlam, {Christopher A.} and Smith, {Mark P.} and Massimo Morfini and Alessandro Gringeri and Elena Santagostino and Savidge, {Geoffrey F.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1046/j.1365-2141.2003.04173.x",
language = "English",
volume = "120",
pages = "808--813",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery

T2 - A pharmacokinetic and efficacy evaluation

AU - Ludlam, Christopher A.

AU - Smith, Mark P.

AU - Morfini, Massimo

AU - Gringeri, Alessandro

AU - Santagostino, Elena

AU - Savidge, Geoffrey F.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - After surgery in haemophilia, haemostasis is difficult to maintain in the presence of an antifactor VIII antibody. This study assessed the pharmacokinetics of recombinant activated factor VII (rFVIIa) and its efficacy in securing post-operative haemostasis in haemophiliacs with inhibitors. Continuous infusion of rFVIIa was evaluated for elective major orthopaedic surgery in nine patients with neutralizing antibodies to FVIII and at high risk of bleeding. After an initial preoperative bolus of 90 μg/kg, rFVIIa was infused at a fixed rate of 50 μg/kg/h for a median of 20 d (range 7-20 d). The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively. The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively. Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55) ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively. Post-operatively, there were bleeds in six patients, which settled readily after a single bolus of rFVIIa (60 μg/kg). There was a good clinical outcome for all patients. These data indicate that rFVIIa infusion at 50 μg/kg/h achieves continuous plasma FVII procoagulant activity in excess of 30 IU/ml (12-15 nmol/l) and provides adequate haemostatic control for inhibitor patients during major orthopaedic surgery.

AB - After surgery in haemophilia, haemostasis is difficult to maintain in the presence of an antifactor VIII antibody. This study assessed the pharmacokinetics of recombinant activated factor VII (rFVIIa) and its efficacy in securing post-operative haemostasis in haemophiliacs with inhibitors. Continuous infusion of rFVIIa was evaluated for elective major orthopaedic surgery in nine patients with neutralizing antibodies to FVIII and at high risk of bleeding. After an initial preoperative bolus of 90 μg/kg, rFVIIa was infused at a fixed rate of 50 μg/kg/h for a median of 20 d (range 7-20 d). The median plasma FVII coagulant activity (FVII:C) at 24 h, 72 h and 20 d after surgery was 38 IU/ml (range 22-169 IU/ml), 45 IU/ml (range 17-88 IU/ml) and 31 IU/ml (range 27-46 IU/ml) respectively. The median plasma FVIIa:C at the same time points was 51 (range 24-211), 63 (range 22-99) and 44 (range 28-76) IU/ml respectively. Median total rFVIIa clearance remained stable during the rFVIIa continuous infusion period and was 40 (range 9-70), 34 (range 17-86) and 48 (range 32-55) ml/kg/h at the end of 24 h, 72 h and 20 d infusion respectively. Post-operatively, there were bleeds in six patients, which settled readily after a single bolus of rFVIIa (60 μg/kg). There was a good clinical outcome for all patients. These data indicate that rFVIIa infusion at 50 μg/kg/h achieves continuous plasma FVII procoagulant activity in excess of 30 IU/ml (12-15 nmol/l) and provides adequate haemostatic control for inhibitor patients during major orthopaedic surgery.

KW - Antifactor VIII antibody

KW - Haemophilia

KW - Orthopaedic surgery

KW - Pharmacokinetic study

KW - Recombinant VIIa

UR - http://www.scopus.com/inward/record.url?scp=0344406183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344406183&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04173.x

DO - 10.1046/j.1365-2141.2003.04173.x

M3 - Article

C2 - 12614214

AN - SCOPUS:0344406183

VL - 120

SP - 808

EP - 813

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -